Our Team

Alise Reicin, MD


Alise Reicin, MD, is CEO and President of Tectonic Therapeutic, Inc., and a Director at Sana Biotechnology.

Alise was previously President, Global Clinical Development at Celgene Corporation, where she oversaw the development and approval of drugs across their pipeline in oncology, hematology and autoimmune diseases and fibrosis. She currently serves on the board of directors of Homology Medicines and Sharsheret. Alise has extensive early and late clinical development experience working across a broad range of therapeutic areas, including oncology, hematology, rheumatology, dermatology, gastroenterology, pain, respiratory and allergic diseases. She played a leadership role which led to the initial approval of 10 novel medicines and the approval of more than 10 indications for an additional 5 drugs.

Alise previously served as Head of Global Clinical Development at EMD Serono. Prior to this, she served as Vice President, Program and Pipeline Leadership, Oncology at Merck and Co. In this capacity, Alise led Merck’s Keytruda (anti-PD-1) program and oversaw the initial development and filing activities worldwide for melanoma and non-small cell lung cancer, and the initiation of development plans in 7 additional indications. Prior to Merck, she was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.

Alise has a BS in biochemistry from Barnard College of Columbia University (summa cum laude) and received her MD from Harvard Medical School (cum laude), where she was enrolled in the Health Sciences and Technology program with MIT.